IBDEI0CZ ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,5950,1,4,0)
 ;;=4^L30.9
 ;;^UTILITY(U,$J,358.3,5950,2)
 ;;=^5009159
 ;;^UTILITY(U,$J,358.3,5951,0)
 ;;=L40.0^^30^385^253
 ;;^UTILITY(U,$J,358.3,5951,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5951,1,3,0)
 ;;=3^Psoriasis Vulgaris
 ;;^UTILITY(U,$J,358.3,5951,1,4,0)
 ;;=4^L40.0
 ;;^UTILITY(U,$J,358.3,5951,2)
 ;;=^5009160
 ;;^UTILITY(U,$J,358.3,5952,0)
 ;;=L40.1^^30^385^256
 ;;^UTILITY(U,$J,358.3,5952,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5952,1,3,0)
 ;;=3^Pustulosis Psoriasis,Generalized
 ;;^UTILITY(U,$J,358.3,5952,1,4,0)
 ;;=4^L40.1
 ;;^UTILITY(U,$J,358.3,5952,2)
 ;;=^5009161
 ;;^UTILITY(U,$J,358.3,5953,0)
 ;;=L40.2^^30^385^11
 ;;^UTILITY(U,$J,358.3,5953,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5953,1,3,0)
 ;;=3^Acrodermatitis Continua
 ;;^UTILITY(U,$J,358.3,5953,1,4,0)
 ;;=4^L40.2
 ;;^UTILITY(U,$J,358.3,5953,2)
 ;;=^5009162
 ;;^UTILITY(U,$J,358.3,5954,0)
 ;;=L40.3^^30^385^255
 ;;^UTILITY(U,$J,358.3,5954,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5954,1,3,0)
 ;;=3^Pustulosis Palmaris et Plantaris
 ;;^UTILITY(U,$J,358.3,5954,1,4,0)
 ;;=4^L40.3
 ;;^UTILITY(U,$J,358.3,5954,2)
 ;;=^5009163
 ;;^UTILITY(U,$J,358.3,5955,0)
 ;;=L40.4^^30^385^157
 ;;^UTILITY(U,$J,358.3,5955,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5955,1,3,0)
 ;;=3^Guttate Psoriasis
 ;;^UTILITY(U,$J,358.3,5955,1,4,0)
 ;;=4^L40.4
 ;;^UTILITY(U,$J,358.3,5955,2)
 ;;=^5009164
 ;;^UTILITY(U,$J,358.3,5956,0)
 ;;=L40.8^^30^385^252
 ;;^UTILITY(U,$J,358.3,5956,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5956,1,3,0)
 ;;=3^Psoriasis NEC
 ;;^UTILITY(U,$J,358.3,5956,1,4,0)
 ;;=4^L40.8
 ;;^UTILITY(U,$J,358.3,5956,2)
 ;;=^271917
 ;;^UTILITY(U,$J,358.3,5957,0)
 ;;=L40.9^^30^385^254
 ;;^UTILITY(U,$J,358.3,5957,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5957,1,3,0)
 ;;=3^Psoriasis,Unspec
 ;;^UTILITY(U,$J,358.3,5957,1,4,0)
 ;;=4^L40.9
 ;;^UTILITY(U,$J,358.3,5957,2)
 ;;=^5009171
 ;;^UTILITY(U,$J,358.3,5958,0)
 ;;=L50.9^^30^385^286
 ;;^UTILITY(U,$J,358.3,5958,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5958,1,3,0)
 ;;=3^Urticaria,Unspec
 ;;^UTILITY(U,$J,358.3,5958,1,4,0)
 ;;=4^L50.9
 ;;^UTILITY(U,$J,358.3,5958,2)
 ;;=^5009204
 ;;^UTILITY(U,$J,358.3,5959,0)
 ;;=L53.8^^30^385^147
 ;;^UTILITY(U,$J,358.3,5959,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5959,1,3,0)
 ;;=3^Erythematous Conditions NEC
 ;;^UTILITY(U,$J,358.3,5959,1,4,0)
 ;;=4^L53.8
 ;;^UTILITY(U,$J,358.3,5959,2)
 ;;=^88044
 ;;^UTILITY(U,$J,358.3,5960,0)
 ;;=L53.9^^30^385^146
 ;;^UTILITY(U,$J,358.3,5960,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5960,1,3,0)
 ;;=3^Erythematous Condition,Unspec
 ;;^UTILITY(U,$J,358.3,5960,1,4,0)
 ;;=4^L53.9
 ;;^UTILITY(U,$J,358.3,5960,2)
 ;;=^5009210
 ;;^UTILITY(U,$J,358.3,5961,0)
 ;;=L54.^^30^385^145
 ;;^UTILITY(U,$J,358.3,5961,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5961,1,3,0)
 ;;=3^Erythema in Diseases Classified Elsewhere
 ;;^UTILITY(U,$J,358.3,5961,1,4,0)
 ;;=4^L54.
 ;;^UTILITY(U,$J,358.3,5961,2)
 ;;=^5009211
 ;;^UTILITY(U,$J,358.3,5962,0)
 ;;=L56.0^^30^385^139
 ;;^UTILITY(U,$J,358.3,5962,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5962,1,3,0)
 ;;=3^Drug Phototoxic Response
 ;;^UTILITY(U,$J,358.3,5962,1,4,0)
 ;;=4^L56.0
 ;;^UTILITY(U,$J,358.3,5962,2)
 ;;=^5009214
 ;;^UTILITY(U,$J,358.3,5963,0)
 ;;=L56.1^^30^385^138
 ;;^UTILITY(U,$J,358.3,5963,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5963,1,3,0)
 ;;=3^Drug Photoallergic Response
 ;;^UTILITY(U,$J,358.3,5963,1,4,0)
 ;;=4^L56.1
 ;;^UTILITY(U,$J,358.3,5963,2)
 ;;=^5009215
 ;;^UTILITY(U,$J,358.3,5964,0)
 ;;=L56.2^^30^385^236
 ;;^UTILITY(U,$J,358.3,5964,1,0)
 ;;=^358.31IA^4^2
